Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Forecast to Reach $2.49 Billion by 2029, Driven by 9.5% CAGR
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Large Is the Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Expected to Be in 2029?
The market size for drugs such as gonadotropin-releasing hormone (GnRH) agonists and antagonists has experienced significant growth in the past years. An increase from $1.57 billion in 2024 to $1.73 billion in 2025 is expected, representing a compound annual growth rate (CAGR) of 9.8%. This substantial growth in the past has been linked to several factors. These factors include escalating cases of hormone-related disorders, an increasing incidence of prostate and breast cancer, heightened awareness regarding reproductive health, escalating demand for assisted reproductive technologies, and a growing preference for hormone therapies in conditions like endometriosis and uterine fibroids.
The market size for gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs is projected to experience a significant expansion in the coming few years. It is predicted to reach $2.49 billion in 2029 with a compound annual growth rate (CAGR) of 9.5%. This surge during the forecasted period can be linked to factors such as the rising preference for less invasive treatments, increased awareness concerning women’s health, the proliferation of combination therapies, enhanced healthcare access in emerging regions, and a growing pipeline of innovative formulations. The forecast period will likely see trends such as advancements in oral GnRH antagonist formulations, innovations in combination therapies with hormonal add-back, incorporation of digital health tools for monitoring reproductive treatments, improvements in clinical trial designs for faster approvals, and the integration of telemedicine in hormone therapy.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25772&type=smp
What Are The Contributors To Demand In The Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market?
The escalating rates of ovarian and prostate cancers are predicted to boost the expansion of the market for gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs in the future. Hormone-sensitive tumors like ovarian and prostate cancers, affected by estrogen and testosterone, are frequently managed through hormone-modulating therapies such as GnRH agonists or antagonists. The surge in these cancers is attributed to the rise in life expectancy, as the likelihood of developing these hormone-dependent cancers escalates with aging. GnRH agonists and antagonists work to treat these cancers by inhibiting the production of sex hormones such as estrogen and testosterone that stimulate the growth of these hormone-sensitive tumors. For instance, by 2023, as per Cancer Australia, a government agency in Australia, approximately 1,786 new instances of ovarian cancer are projected to be diagnosed in the country. Moreover, the odds of women being diagnosed with ovarian cancer by the age of 85 is about 1 in 87 (or a 1.2% risk). Consequently, the growing prevalence of ovarian and prostate cancers is facilitating the rise of the gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs market.
What Segmentation Categories Are Included In The Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Analysis?
The gonadotropin-releasing hormone (gnrh) agonists and antagonists drugs market covered in this report is segmented –
1) By Drug Type: GnRH Agonists, Leuprorelin, Goserelin, Triptorelin, Histrelin, Buserelin, GnRH Antagonists, Degarelix, Abarelix, Other Drug Types
2) By Application: Gynecology, Oncology, Other Applications
3) By End-User: Hospitals, Specialty Clinics, Other End-Users
Subsegments:
1) By GnRH Agonists: Deslorelin, Gonadorelin, Zoladex Long-Acting Goserelin Variant, Lupron Depot-Ped, Sustained-Release Microsphere Formulations
2) By Leuprorelin: Depot Injection, Implant, Combination Therapy Formulations
3) By Goserelin: Subcutaneous Implant, Oncology-Specific Formulation, Gynecology-Specific Formulation
4) By Triptorelin: Intramuscular Injection, Long-Acting (1-, 3-, 6-Month) Depot, Fertility Treatment Formulation
5) By Histrelin: Subcutaneous Implant, Pediatric (Precocious Puberty) Formulation, Adult Prostate Cancer-Specific Version
6) By Buserelin: Nasal Spray, Subcutaneous Injection, In Vitro Fertilization And Fertility Cycle Formulations
7) By GnRH Antagonists: Teverelix DP, Elagolix, Relugolix, Ganirelix, Linzagolix
8) By Degarelix: Subcutaneous Injection, Monthly Dosing, Prostate Cancer-Specific Formulation
9) By Abarelix: Intramuscular Injection, Advanced Prostate Cancer, Short-Acting Formulation
10) By Other Drug Types: Subcutaneous Injection, In Vitro Fertilization-Specific Use, Multiple Dosing Regimens
What Upcoming Trends Are Expected To Impact The Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Globally?
Leading entities in the market for gonadotropin-releasing hormone (GnRH) antagonists and agonists drugs are concentrating on the innovation of novel solutions like oral GnRH receptor antagonists. This focus is geared towards improving patient comfort, boosting adherence to treatment, and minimizing the demand for injection therapies. An oral GnRH receptor antagonist is a medical pill that obstructs GnRH receptors, swiftly reducing sex hormone levels. This helps in the management of hormone-related disorders, such as endometriosis and prostate cancer. In March 2024, for example, Japanese pharmaceutical corporation Sumitomo Pharma Co. Ltd., released news of Health Canada’s approval of ORGOVYX (relugolix)—the first ever and sole oral androgen deprivation therapy (ADT) for progressive prostate cancer, within Canada. ORGOVYX is an oral GnRH receptor antagonist administered daily, which inhibits testosterone production, which is a significant instigator of prostate cancer development. The approval of this drug was influenced by the findings of the Phase 3 HERO study, exhibiting effective and continuous testosterone suppression, lowered cardiovascular event rates, and castration resistance-free survival similar to standard injectable treatments.
Who Are The Top-Ranked Companies In The Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Today?
Major companies operating in the gonadotropin-releasing hormone (gnrh) agonists and antagonists drugs market are Pfizer Inc., AbbVie Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Merck KGaA, Intas Pharmaceuticals Limited, Sumitomo Pharma Co. Ltd., Ipsen S.A., Dr. Reddy’s Laboratories Limited, Cipla Limited, Gedeon Richter Plc, Lupin Limited, Zydus Lifesciences Limited, Gland Pharma Limited, Bachem Holding AG, Kissei Pharmaceutical Co. Ltd., Aska Pharmaceutical Co. Ltd., Ferring International Center S.A., Tolmar Inc., Debiopharm International SA, TerSera Therapeutics LLC, TiumBio Co. Ltd.
Get The Full Report Here:
How Is Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Adoption Varying Across Different Regions And Sectors?
North America was the largest region in the gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gonadotropin-releasing hormone (gnrh) agonists and antagonists drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=25772&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
